Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 4,504,900 | 4,412,600 | 3,953,600 | 4,338,400 | 8,075,300 |
| Depreciation Amortization | 543,700 | 482,900 | 421,000 | 341,400 | 286,200 |
| Income taxes - deferred | -785,400 | -757,300 | -837,800 | -746,400 | -147,100 |
| Accounts receivable | 498,100 | -554,000 | -338,800 | 707,800 | -1,927,400 |
| Other Working Capital | 532,600 | -618,300 | -94,100 | -243,300 | -1,916,500 |
| Other Operating Activity | -315,000 | 1,454,600 | 1,490,100 | 617,000 | 2,710,800 |
| Operating Cash Flow | $4,978,900 | $4,420,500 | $4,594,000 | $5,014,900 | $7,081,300 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 587,900 | -1,590,100 | -2,203,800 | -1,937,400 | -4,832,800 |
| PPE Investments | -898,400 | -735,800 | -718,600 | -590,100 | -551,900 |
| Net Acquisitions | -3,300 | -16,500 | -54,900 | -230,300 | N/A |
| Purchase Sale Intangibles | -315,300 | -125,700 | -207,800 | -1,026,800 | 0 |
| Other Investing Activity | -315,300 | -125,700 | -207,800 | -1,026,800 | 0 |
| Investing Cash Flow | $-629,100 | $-2,468,100 | $-3,185,100 | $-3,784,600 | $-5,384,700 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 635,900 | 1,465,300 | 1,145,500 | 1,519,500 | 1,672,300 |
| Common Stock Repurchased | -3,970,700 | -3,632,400 | -2,935,600 | -2,528,500 | -2,678,100 |
| Dividend Paid | -370,300 | N/A | N/A | N/A | N/A |
| Other Financing Activity | -10,300 | -33,400 | 0 | 0 | 0 |
| Financing Cash Flow | $-3,715,400 | $-2,200,500 | $-1,790,100 | $-1,009,000 | $-1,005,800 |
| Exchange Rate Effect | 300 | -700 | -400 | 0 | 0 |
| Beginning Cash Position | 2,489,000 | 2,737,800 | 3,119,400 | 2,898,100 | 2,207,300 |
| End Cash Position | 3,123,700 | 2,489,000 | 2,737,800 | 3,119,400 | 2,898,100 |
| Net Cash Flow | $634,700 | $-248,800 | $-381,600 | $221,300 | $690,800 |
| Free Cash Flow | |||||
| Operating Cash Flow | 4,978,900 | 4,420,500 | 4,594,000 | 5,014,900 | 7,081,300 |
| Capital Expenditure | -898,400 | -755,900 | -718,600 | -590,100 | -551,900 |
| Free Cash Flow | 4,080,500 | 3,664,600 | 3,875,400 | 4,424,800 | 6,529,400 |